TD Cowen downgraded Crispr Therapeutics to Underperform from Market Perform with a $30 price target. Shares appear overvalued based on the Casgevy launch, the analyst tells investors in a research note. The approval of Casgevy is a major scientific achievement and milestone for the field of gene editing, but the firm doesn’t believe that it will be used broadly enough to support this elevated valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Vertex (NASDAQ:VRTX), CRISPR Therapeutics Slip despite Sickle Cell Treatment Approval
- Crispr says Casgevy approval triggers $200M milestone payment
- Vertex sets $2.2M as U.S. wholesale acquisition cost for Casgevy
- Vertex and Crispr announce FDA approval of Casgevy for sickle cell disease
- Mizuho sees black box warning just for Bluebird, not Crispr